Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Purpose Synaptic abnormalities are associated with many brain disorders. Recently, we developed a novel synaptic vesicle glycoprotein 2A (SV2A) radiotracer [18 F]SynVesT-1 and demonstrated its excellent imaging and binding properties in nonhuman primates. The aim of this study was to perform dosimetry calculations in nonhuman primates and to evaluate this tracer in humans and assess its test-retest reliability in comparison with [11 C]UCB-J.Methods Three rhesus monkeys underwent whole body dynamic PET scanning to estimate the absorbed dose. PET scans in six healthy human subjects were acquired. Time-activity curves (TACs) were generated with defined regions of interest (ROI). Reproducibility of distribution volume (V T) values and its sensitivity to scan duration were assessed with the one-tissue compartment (1TC) model. Non-displaceable binding potential (BP ND) was calculated using centrum semiovale as the reference region.Results The dosimetry study showed high uptake in the urinary bladder and brain. In humans, [18 F]SynVesT-1 displayed high uptake with maximum SUV of ~10 and appropriate kinetics with a quick rise in tracer uptake followed by a gradual clearance. Mean 1TC V T values (mL/cm 3) ranged from 3.4 (centrum semiovale) to 19.6 (putamen) and were similar to those of [11 C]UCB-J. Regional BP ND values were 2.7-4.7 in gray matter areas, and mean BP ND values across all ROIs were ~ 21% higher than those of [11 C]UCB-J. The absolute test-retest variability of V T and BP ND was excellent (< 9%) across all brain regions.Conclusions [18 F]SynVesT-1 demonstrates outstanding characteristics in humans: fast and high brain uptake, appropriate tissue kinetics, high levels of specific binding, and excellent test-retest reproducibility of binding parameters. As such, [18 F]SynVesT-1 is proved to be a favorable radiotracer for SV2A imaging and quantification in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In humans, [ 18 F]SynVesT-1 displayed outstanding characteristics, i.e., very high brain uptake, fast and reversible kinetics, excellent test-retest reproducibility and binding specificity to SV2A”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [124]
In the citing paper
“Excellent test-retest reproducibility and low noise V T images can be obtained”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [124]
Citations
Cites
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319 · cited 1×
“The summed PET image was then co-registered to the subject’s T1weighted MR image (6-parameter affine registration), which was subsequently co-registered to the automated anatomical labeling (AAL) template [30] in Montreal Neurological Institute (MNI) [31] space using a nonlinear transformation (Bioimage suite) [32].”
MethodSchizophrenia risk from complex variation of complement component 4
Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., et al. (2016) · Nature · doi:10.1038/nature16549 · Cited by 2,394 · cited 1×
“Synaptopathy, change and/or abnormality in the function and structure of synapses, has been frequently observed in patients with neurodegenerative disorders including Alzheimer’s disease (AD) [1, 2], Parkinson’s disease (PD) [3], and epilepsy [4, 5], as well as psychiatric diseases such as depression [6], schizophreni…”
BackgroundDecreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636 · cited 1×
“Synaptopathy, change and/or abnormality in the function and structure of synapses, has been frequently observed in patients with neurodegenerative disorders including Alzheimer’s disease (AD) [1, 2], Parkinson’s disease (PD) [3], and epilepsy [4, 5], as well as psychiatric diseases such as depression [6], schizophreni…”
BackgroundThe synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 1×
“It has also been identified as the binding site of the anti-epileptic drugs levetiracetam and brivaracetam [13].”
BackgroundEnhancement of MR Images Using Registration for Signal Averaging
Holmes, C. J., Hoge, R., Collins, L., Woods, R., Toga, A. W., & Evans, A. C. (1998) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199803000-00032 · Cited by 1,417 · cited 2×
“The summed PET image was then co-registered to the subject’s T1weighted MR image (6-parameter affine registration), which was subsequently co-registered to the automated anatomical labeling (AAL) template [30] in Montreal Neurological Institute (MNI) [31] space using a nonlinear transformation (Bioimage suite) [32].”
MethodStabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,350
Loss of mTOR-Dependent Macroautophagy Causes Autistic-like Synaptic Pruning Deficits
Tang, G., Gudsnuk, K., Kuo, S.-H., Cotrina, M. L., Rosoklija, G., Sosunov, A., Sonders, M. S., Kanter, E., Castagna, C., Yamamoto, A., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.040 · Cited by 1,146 · cited 1×
“Synaptopathy, change and/or abnormality in the function and structure of synapses, has been frequently observed in patients with neurodegenerative disorders including Alzheimer’s disease (AD) [1, 2], Parkinson’s disease (PD) [3], and epilepsy [4, 5], as well as psychiatric diseases such as depression [6], schizophreni…”
BackgroundDecreased expression of synapse-related genes and loss of synapses in major depressive disorder
Kang, H. J., Voleti, B., Hajszan, T., Rajkowska, G., Stockmeier, C. A., Licznerski, P., Lepack, A., Majik, M. S., Jeong, L. S., Banasr, M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2886 · Cited by 808 · cited 1×
“Synaptopathy, change and/or abnormality in the function and structure of synapses, has been frequently observed in patients with neurodegenerative disorders including Alzheimer’s disease (AD) [1, 2], Parkinson’s disease (PD) [3], and epilepsy [4, 5], as well as psychiatric diseases such as depression [6], schizophreni…”
BackgroundSpecific absorbed fractions of energy at various ages from internal photon sources: 6, Newborn
Cristy, M., & Eckerman, K. F. (1987) · doi:10.2172/6202949 · Cited by 692
Imaging synaptic density in the living human brain
Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6667 · Cited by 575 · cited 1×
“The decreased binding corresponded well with previous tissue analysis, and the binding asymmetry was more specifically localized to the seizure onset zone (SOZ), while the change in [(18)F]FDG uptake also extended to the adjacent regions [14].”
BackgroundSelf-citationLower synaptic density is associated with depression severity and network alterations
Holmes, S. E., Scheinost, D., Finnema, S. J., Naganawa, M., Davis, M. T., DellaGioia, N., Nabulsi, N., Matuskey, D., Angarita, G. A., Pietrzak, R. H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09562-7 · Cited by 484 · cited 1×
“Lower SV2A densities were observed in the frontal cortex and hippocampus regions of individuals with severe depressive symptoms [21].”
BackgroundSelf-citationDifferential expression of synaptic vesicle protein 2 (SV2) isoforms
Bajjalieh, S., Frantz, G., Weimann, J., McConnell, S., & Scheller, R. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-09-05223.1994 · Cited by 440 · cited 1×
“SV2A is the most abundant and widely distributed in the brain [10].”
BackgroundSynaptic loss in Alzheimer's disease and other dementias
Hamos, J. E., DeGennaro, L. J., & Drachman, D. A. (1989) · Neurology · doi:10.1212/wnl.39.3.355 · Cited by 432
Chen, M.-K., Mecca, A. P., Naganawa, M., Finnema, S. J., Toyonaga, T., Lin, S.-F., Najafzadeh, S., Ropchan, J., Lu, Y., McDonald, J. W., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1836 · Cited by 431 · cited 1×
“The binding potential of [(11)C]UCB-J was ~20% lower in the hippocampus of early AD patients when compared to cognitively normal subjects [18, 19].”
BackgroundSelf-citationAbnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415 · cited 1×
“SV2A is believed to regulate action potential-dependent neurotransmitter release [11] and modulate the expression and trafficking of the calcium sensor protein synaptotagmin [12].”
BackgroundSpecific absorbed fractions of energy at various ages from internal photon sources: 1, Methods
Cristy, M., & Eckerman, K. F. (1987) · doi:10.2172/6233735 · Cited by 310
Nabulsi, N. B., Mercier, J., Holden, D., Carré, S., Najafzadeh, S., Vandergeten, M.-C., Lin, S.-F., Deo, A., Price, N., Wood, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168179 · Cited by 296
Self-citationIn vivo measurement of widespread synaptic loss in Alzheimer’s disease with SV2A PET
Mecca, A. P., Chen, M., O'Dell, R. S., Naganawa, M., Toyonaga, T., Godek, T. A., Harris, J. E., Bartlett, H. H., Zhao, W., Nabulsi, N. B., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12097 · Cited by 288 · cited 1×
“The binding potential of [(11)C]UCB-J was ~20% lower in the hippocampus of early AD patients when compared to cognitively normal subjects [18, 19].”
BackgroundSelf-citationOnwordi, E. C., Halff, E. F., Whitehurst, T., Mansur, A., Cotel, M.-C., Wells, L., Creeney, H., Bonsall, D., Rogdaki, M., Shatalina, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14122-0 · Cited by 243 · cited 1×
“Patients with schizophrenia, when comparing to healthy controls, exhibited decreased [(11)C]UCB-J uptake in the frontal and anterior cingulate cortices [22].”
BackgroundColumn-switching HPLC for the analysis of plasma in PET imaging studies
Hilton, J., Yokoi, F., Dannals, R. F., Ravert, H. T., Szabo, Z., & Wong, D. F. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00125-6 · Cited by 222 · cited 1×
“Metabolite analysis was performed using the column-switching HPLC method [29] to determine the parent fraction.”
MethodFinnema, S. J., Nabulsi, N. B., Mercier, J., Lin, S.-F., Chen, M.-K., Matuskey, D., Gallezot, J.-D., Henry, S., Hannestad, J., Huang, Y., et al. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17724947 · Cited by 218 · cited 6×
“We compared the test-retest reproducibility (aTRV) for K1, VT, VT/fp, and BPND of [ (18)F]SynVesT-1 with those of [(11)C]UCB-J published previously [16].”
BackgroundMethodResultSelf-citationSynaptic Changes in Parkinson Disease Assessed with in vivo Imaging
Matuskey, D., Tinaz, S., Wilcox, K. C., Naganawa, M., Toyonaga, T., Dias, M., Henry, S., Pittman, B., Ropchan, J., Nabulsi, N., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25682 · Cited by 180 · cited 1×
“Patients with PD showed a significant decrease of [(11)C]UCB-J uptake in the substantia nigra region, along with a global reduction across the brain [20].”
BackgroundSelf-citationRadiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates
Quinn, B., Dauer, Z., Pandit-Taskar, N., Schoder, H., & Dauer, L. T. (2016) · BMC Medical Imaging · doi:10.1186/s12880-016-0143-y · Cited by 177
Cotrafficking of SV2 and synaptotagmin at the synapse
Yao, J., Nowack, A., Kensel-Hammes, P., Gardner, R. G., & Bajjalieh, S. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4781-09.2010 · Cited by 164 · cited 1×
“SV2A is believed to regulate action potential-dependent neurotransmitter release [11] and modulate the expression and trafficking of the calcium sensor protein synaptotagmin [12].”
BackgroundRobinson, J. L., Molina-Porcel, L., Corrada, M. M., Raible, K., Lee, E. B., Lee, V. M.-Y., Kawas, C. H., & Trojanowski, J. Q. (2014) · Brain · doi:10.1093/brain/awu190 · Cited by 157 · cited 1×
“Synaptopathy, change and/or abnormality in the function and structure of synapses, has been frequently observed in patients with neurodegenerative disorders including Alzheimer’s disease (AD) [1, 2], Parkinson’s disease (PD) [3], and epilepsy [4, 5], as well as psychiatric diseases such as depression [6], schizophreni…”
BackgroundProper, E. A., Oestreicher, A. B., Jansen, G. H., Veelen, C. W. M. V., van Rijen, P. C., Gispen, W. H., & de Graan, P. N. E. (2000) · Brain · doi:10.1093/brain/123.1.19 · Cited by 151 · cited 1×
“Synaptopathy, change and/or abnormality in the function and structure of synapses, has been frequently observed in patients with neurodegenerative disorders including Alzheimer’s disease (AD) [1, 2], Parkinson’s disease (PD) [3], and epilepsy [4, 5], as well as psychiatric diseases such as depression [6], schizophreni…”
BackgroundNaganawa, M., Li, S., Nabulsi, N., Henry, S., Zheng, M.-Q., Pracitto, R., Cai, Z., Gao, H., Kapinos, M., Labaree, D., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.249144 · Cited by 138
Self-citationAssessment of a white matter reference region for 11 C-UCB-J PET quantification
Rossano, S., Toyonaga, T., Finnema, S. J., Naganawa, M., Lu, Y., Nabulsi, N., Ropchan, J., De Bruyn, S., Otoul, C., Stockis, A., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19879230 · Cited by 126 · cited 2×
“Although centrum semiovale has been thoroughly evaluated as a potential reference region for [(11)C]UCB-J [33], its VT value was greater than the non-displaceable volume of distribution (VND) estimated from blocking studies.”
BackgroundMethodSelf-citationLi, S., Cai, Z., Wu, X., Holden, D., Pracitto, R., Kapinos, M., Gao, H., Labaree, D., Nabulsi, N., Carson, R. E., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00526 · Cited by 124 · cited 5×
“[(18)F]SynVesT-1 was synthesized as previously described [23].”
BackgroundResultSelf-citationConstantinescu, C. C., Tresse, C., Zheng, M., Gouasmat, A., Carroll, V. M., Mistico, L., Alagille, D., Sandiego, C. M., Papin, C., MAREK, K. L., et al. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-018-1260-5 · Cited by 80
Toyonaga, T., Smith, L. M., Finnema, S. J., Gallezot, J.-D., Naganawa, M., Bini, J., Mulnix, T., Cai, Z., Ropchan, J., Huang, Y., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223867 · Cited by 79 · cited 1×
“Currently, [(11)C]UCB-J is being broadly used in identifying disease-specific synaptic deficits in multiple brain diseases, including AD, PD, epilepsy, depression, and schizophrenia, and in monitoring drug treatment effect [17].”
MethodSelf-citationCrèvecœur, J., Kaminski, R. M., Rogister, B., Foerch, P., Vandenplas, C., Neveux, M., Mazzuferi, M., Kroonen, J., Poulet, C., Martin, D., et al. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12054 · Cited by 68 · cited 1×
“Synaptopathy, change and/or abnormality in the function and structure of synapses, has been frequently observed in patients with neurodegenerative disorders including Alzheimer’s disease (AD) [1, 2], Parkinson’s disease (PD) [3], and epilepsy [4, 5], as well as psychiatric diseases such as depression [6], schizophreni…”
BackgroundJin, X., Chan, C., Mulnix, T., Panin, V., Casey, M. E., Liu, C., & Carson, R. E. (2013) · Physics in Medicine and Biology · doi:10.1088/0031-9155/58/16/5567 · Cited by 63 · cited 1×
“Event-by-event motion correction [28] was included in the reconstruction based on measurements with the Polaris Vicra sensor (NDI Systems, Waterloo, Canada) with reflectors mounted on a cap worn by the subject.”
MethodSelf-citationBioImage Suite: An integrated medical image analysis suite
Papademetris, X., Jackowski, M., Rajeevan, N., Constable, R. T., & Staib, L. (2005) · The Insight Journal · doi:10.54294/vb5z20 · Cited by 46
Functional changes in the frontal cortex in Parkinson’s disease using a rat model
Hou, Z., Lei, H. C., Hong, S., Sun, B., Fang, K., Lin, X., Liu, M., Yew, D. T. W., & Liu, S. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2009.07.101 · Cited by 27 · cited 1×
“Synaptopathy, change and/or abnormality in the function and structure of synapses, has been frequently observed in patients with neurodegenerative disorders including Alzheimer’s disease (AD) [1, 2], Parkinson’s disease (PD) [3], and epilepsy [4, 5], as well as psychiatric diseases such as depression [6], schizophreni…”
Background
Research works printed but not linked: 1
- Carson RE, Barker W, Liow J-S, Adler S, Johnson C. Design of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction of the HRRT. IEEE Nucl Sci Symp Conf Rec. 2003:M16–6.
Cited by
Radiopharmaceuticals and their applications in medicine
Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 284
Synaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123
“Several [18F]-labeled candidates have now been evaluated (Patel et al., 2020), especially UCBJ derivatives including [18F]MNI-1126 (Constantinescu et al., 2019), also named [18F]-SDM-8 and described by Li et al. (2019a) and then referred as [18F]-SynVesT-1 (Li et al., 2021; Naganawa et al., 2021b).”
MethodImaging of Synaptic Density in Neurodegenerative Disorders
Carson, R. E., Naganawa, M., Toyonaga, T., Koohsari, S., Yang, Y., Chen, M.-K., Matuskey, D., & Finnema, S. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263201 · Cited by 104
“Excellent test–retest reproducibility and low-noise VT images can be obtained with the 1TC model for (11)C-UCB-J (37) and (18)F-SynVesT-1 (31,32).”
BackgroundMethodSelf-citationRibarič, S. (2023) · Biomedicines · doi:10.3390/biomedicines11020355 · Cited by 66
Tang, Y., Yu, J., Zhou, M., Li, J., Long, T., Li, Y., Feng, L., Chen, D., Yang, Z., Huang, Y. H., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05665-w · Cited by 38
“Compared to 11C-UCB-J, the newly reported SV2A radioligand 18F-SynVesT-1 has a longer half-life and superior signal-to-noise ratio [14, 15].”
Self-citation
Metadata
- Authors
- Li, S., Naganawa, M., Pracitto, R., Najafzadeh, S., Holden, D., Henry, S., Matuskey, D., Emery, P. R., Cai, Z., Ropchan, J., Nabulsi, N., Carson, R. E., & Huang, Y.
- Affiliations
- Yale University (US)
- Corresponding author
- Li, Songye
- Huang, Yiyun
- ORCID
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2021-01-08
- Volume
- 48
- Issue
- 5
- Pages
- 1327-1338
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W3118626742
- Cited by
- 61
- References
- 35
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 19 · 2023: 8 · 2022: 9 · 2021: 3
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG052560, R01AG065474)
- Michael J. Fox Foundation for Parkinson's Research
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- [18F]SynVesT-1, SV2A, test-retest reproducibility, dosimetry, non-human primates, rhesus monkeys, [11C]UCB-J, binding potential, volume of distribution, time-activity curves, one-tissue compartment model, brain uptake
- MeSH terms
- Animals, Brain, Fluorine Radioisotopes, Glycoproteins, Pyridines, Pyrrolidinones, Synaptic Vesicles, Reproducibility of Results, Radiopharmaceuticals, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.